CClinicalTrials.gg
CompletedNCT03133286RADIANTUpdated Aug 7, 2024

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

An observational study in Radiation Therapy, Cancer and Cancer of Anus, sponsored by DxTerity Diagnostics. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by DxTerity Diagnostics · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Study summary

Collect blood samples and associated clinical data prior to, during, and post radiation treatment.

Read the detailed description

In order to further refine and independently validate the performance of DxTerity's test developed during the previous pilot study, the study will collect pre-, during, and post-irradiation blood samples and associated clinical and self-reported information from up to five hundred (500) subjects for analysis. Patients with a diagnosis of primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer requiring radiation treatment to the primary disease site will be included in the study. Combining chemotherapy is allowed.

Blood samples for this study will be collected from cancer patients scheduled to undergo radiation therapy prior to and either during or after treatment. Approximately 150μL of blood per time point will be obtained via fingerstick remotely, from the participant's home or doctor's office; participation in this study will not affect any aspect of patient treatment. Samples will be collected using DxTerity's proprietary DxCollect® MCD Fingerstick Kit (MCD).

02

Conditions studied

  • Radiation Therapy
  • Cancer
  • Cancer of Anus
  • Cancer of Bladder
  • Cancer of Cervix
  • Cancer of Colon
  • Cancer of Rectum
  • Cancer of Esophagus
  • Cancer of Gallbladder
  • Cancer of Liver
  • Cancer of Ovary
  • Cancer of Pancreas
  • Cancer of Prostate
  • Cancer of Kidney and Renal Pelvis
  • Cancer of Stomach
  • Cancer of Testis
  • Cancer of Uterus
  • Cancer of Uterus and Cervix
  • Cancer of Kidney

Keywords

  • Anal Cancer
  • Bladder
  • Cervical
  • Colorectal
  • Esophageal
  • Gallbladder
  • Liver
  • Ovarian
  • Pancreas
  • Pancreatic
  • Prostate
  • Rectal
  • Renal
  • Kidney
  • Stomach
  • Testicular
  • Uterine
  • Cancer
  • Radiation Therapy
  • Radiation Treatment
03

In context

Pancreatic Neoplasms

3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.

This study's enrollment of 16 is below the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

DxTerity Diagnostics is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients diagnosed with a primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) tumors being treated with radiation therapy.

Inclusion criteria

  1. Male and female patients age 18 or older
  2. Have a permanent address in the United States for the duration of the study
  3. Diagnosed with a primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer
  4. Planned radiation therapy to the abdominal/pelvic area as part of clinical care
  5. Able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  1. Receipt of radiation within three (3) months to abdominal/pelvic area prior to scheduled start of Radiation Treatment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Obtain pre- and post-irradiation participant-collect blood samples

    Obtain pre-irradiation participant-collected blood sample and associated clinical data from cancer patients undergoing abdominal/pelvic radiation therapy as part of clinical care.

    Time frame: 1.5 years

07

Study locations

4 sites
  • DxTerity Diagnostics
    Compton, California 90220, United States
  • 21st Century Oncology
    Bradenton, Florida 34202, United States
  • 21st Century Oncology
    Fort Myers, Florida 33908, United States
  • 21st Century Oncology
    Plantation, Florida 33324, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03133286
Lead sponsor
DxTerity Diagnostics
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Apr 28, 2017
Start date
Apr 6, 2017
Primary completion
Feb 24, 2020
Completion
Feb 25, 2020
Last update
Aug 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion